Introducing our Medical Advisory Board
The Foundation’s Board of Directors established a Medical Advisory Board to be composed of reputable cancer researchers who are physicians treating pediatric cancer. Facilitating the MAB’s objectives is Jim McAllister of Asheville, NC, who also serves on the Foundation’s Board. Jim brings his 35+ years of corporate management experience to help make certain that every dollar donated to SebastianStrong is used to increase awareness and find less toxic, more targeted cures for childhood cancers. Please direct questions to him at firstname.lastname@example.org.
Dr. David Loeb
Dr. David Loeb graduated from Johns Hopkins University and then moved to New York and obtained his MD and PhD from the Columbia University College of Physicians and Surgeons. He returned to Johns Hopkins, where he completed his internship and residency in Pediatrics and his fellowship in Pediatric Hematology and Oncology. He joined the faculty at Johns Hopkins, where he practiced and performed research for 17 years. Dr. Loeb joined the faculty at Children’s Hospital at Montefiore (CHAM), where he serves as Director of Pediatric Hematology, Oncology, and Marrow & Blood Cell Transplantation, in 2017. He is also a member of the Department of Developmental and Molecular Biology at the Albert Einstein College of Medicine.
Dr. Loeb is Director of the Sarcoma Program and is a member of the Bone Marrow Transplant Program at CHAM. He also has expertise in the care of children with other solid tumors, with acute myeloid leukemia and in the application of immunotherapy to childhood cancer. Dr. Loeb has an active translational research laboratory focused on understanding bone tumor metastasis. His laboratory developed a clinically relevant mouse model of sarcoma metastasis, and has used this model to perform preclinical testing of novel agents that can interfere with this process. In addition, Dr. Loeb is also studying the role of an enzyme called RNA helicase DDX3 in Ewing's Sarcoma biology, especially how this enzyme affects the repair of damaged DNA. Dr. Loeb is also actively involved in clinical research, including the development of radiopharmaceutical agents for the treatment of bone metastases and the development of a small molecule inhibitor of DDX3. He serves as the Coordinating Physician for an international Phase I study of an immune checkpoint inhibitor for pediatric solid tumors, and he has directed a clinical trial of reduced intensity haploidentical bone marrow transplantation for children with high risk solid tumors. As an offshoot of his laboratory work, Dr. Loeb is involved in the development of biomarkers of metastatic risk and of minimal residual disease in children, adolescents, and young adults with sarcomas.
Dr. Matteo Trucco
Dr. Matteo Trucco is the Director of the Phase 1 Pediatric Clinical Research Program in Pediatric Hematology/Oncology at the Sylvester Comprehensive Cancer Center at University of Miami-Miller School of Medicine. Dr. Trucco completed his undergraduate training at the University of Pennsylvania with a B.A. in Biology and Philosophy of Science. He graduated at the top of his class from Temple University School of Medicine where he was inducted in the Alpha Omega Alpha Honor Medical Society during his Junior year and received numerous awards including the Benjamin and Mary Siddons Measey Foundation Scholarship, and the Waldo E. Nelson M.D. Pediatric Award. He then completed his Pediatrics Internship and Residency at Rainbow Babies and Children’s Hospital/ Case Western Reserve University where he was again acknowledged with several awards and commendations for his patient care.
Dr. Trucco’s Pediatric Hematology/Oncology training was completed at Johns Hopkins University and the National Cancer Institute. Upon completing his fellowship training, Dr. Trucco was recruited to Texas Children’s Hospital and awarded a coveted position in the K12 Faculty Fellowship in Pediatric Oncology Clinical Research. During his four years as faculty at Texas Children’s Hospital, Dr. Trucco obtained a Certificate of Added Qualification in Clinical Investigations and was an active member of the Pediatric Oncology Phase 1 team as well as the local PI for industry sponsored clinical trials and studied the altered metabolism of pediatric bone tumors and how to use these alterations to develop new therapies for these cancers.
Dr. Trucco has numerous peer-reviewed publication and runs several clinical trials studying new treatments for childhood cancers. He is actively developing additional trials testing innovative strategies to develop more effective and less toxic therapies for children with cancer. In addition to taking on the responsibility for the coordination and management of Sylvester's pediatric early phase clinical trials, Dr. Trucco is the only Pediatric Sarcoma specialist in Southern Florida and has served as a consultant to and received referrals from Pediatric Oncology colleagues throughout Miami-Dade, Broward and Palm Beach counties, as well as several Caribbean and South American countries.